Step-Up Therapy After Symbicort for Asthma
If asthma remains uncontrolled on Symbicort (budesonide/formoterol), the preferred step-up approach is to increase to high-dose ICS/LABA (Symbicort 160/4.5 two inhalations twice daily for adults ≥12 years), and if this fails to achieve control, add oral corticosteroids as the next step.
Initial Assessment Before Stepping Up
Before escalating therapy, verify:
- Inhaler technique is correct - improper technique is a common cause of apparent treatment failure
- Medication adherence - patients often miss doses
- Environmental triggers are controlled - ongoing allergen or irritant exposure undermines treatment
- Correct diagnosis - ensure this is truly asthma and not an asthma mimic
Stepwise Escalation Algorithm
If Currently on Low-to-Medium Dose Symbicort (80/4.5 or 160/4.5 once or twice daily):
Step 1: Maximize ICS/LABA Dose
- Increase to Symbicort 160/4.5, two inhalations twice daily (maximum recommended dose for adults/adolescents ≥12 years)
- This represents high-dose ICS/LABA therapy
- Reassess control after 1-2 weeks, as maximum benefit may take up to 2 weeks 3
If Already on Maximum Dose Symbicort (160/4.5 two inhalations twice daily):
Step 2: Consider SMART Regimen First
- Before adding a third medication, consider switching to Symbicort Maintenance and Reliever Therapy (SMART)
- Use Symbicort 160/4.5 two inhalations twice daily as maintenance, PLUS additional inhalations as needed for symptom relief (up to 12 total inhalations per day)
- This approach reduces severe exacerbations by 29-30% compared to stepping up or continuing fixed-dose ICS/LABA plus SABA 4, 5
- SMART provides anti-inflammatory relief with each rescue dose, unlike SABA-only rescue therapy
Step 3: Add Oral Corticosteroids
- If high-dose ICS/LABA (with or without SMART) fails to control asthma, add oral corticosteroids (1-2 mg/kg/day, generally not exceeding 60 mg/day)
- Use the lowest possible dose, preferably on alternate days
- Make persistent attempts to reduce systemic corticosteroids once control is achieved
- Consult an asthma specialist at this stage - this is strongly recommended for severe persistent asthma 2
What NOT to Do
Adding a third long-term controller medication (leukotriene modifier, theophylline, or another LABA) to high-dose ICS/LABA is NOT supported by evidence and should not be done to avoid oral corticosteroids. Studies show no benefit for adding these agents to the combination of high-dose ICS and LABA 2.
Critical Pitfall: Do not add another LABA (salmeterol, additional formoterol, arformoterol) to Symbicort - this increases cardiovascular risk and mortality without benefit 3.
Age-Specific Considerations
Adults and Adolescents ≥12 years:
- Maximum dose: Symbicort 160/4.5, two inhalations twice daily
- SMART regimen: up to 12 total inhalations daily 3, 5
Children 6 to <12 years:
- Maximum dose: Symbicort 80/4.5, two inhalations twice daily
- Step-up beyond this requires specialist consultation 3
Monitoring and Safety
- Never exceed 2 inhalations twice daily for maintenance dosing (unless using SMART regimen)
- With SMART, never exceed 12 total inhalations in a single day (54 μg formoterol total) 3, 5
- Monitor for oral candidiasis - have patients rinse mouth after each use 3
- Watch for signs of systemic corticosteroid effects if oral steroids are added
- Increasing rescue inhaler use signals deteriorating control and requires immediate reassessment 3
Evidence Quality Note
The 2020 NAEPP guidelines 1 provide the most current framework, though specific step-up recommendations from Steps 3-4 are detailed in the 2002 guidelines 2. The SMART approach has robust recent evidence from 2022 meta-analyses 4 showing superiority over traditional fixed-dose escalation. The FDA label 3 provides critical safety boundaries that must not be exceeded.
The key principle: Maximize ICS/LABA dosing first, consider SMART if not already implemented, then add oral corticosteroids only when high-dose ICS/LABA fails. Do not add third-line agents like leukotriene modifiers or theophylline at this stage.